Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
01
12
2021
accepted:
21
04
2022
pubmed:
16
5
2022
medline:
23
8
2022
entrez:
15
5
2022
Statut:
ppublish
Résumé
PERSIST was a prospective, non-interventional, long-term, German multicentre study of patients with moderate-to-severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23, in a real-world setting. Evaluation of the efficacy and safety of guselkumab, and its effect on health-related quality of life (HRQoL), in patients with moderate-to-severe psoriasis who have received 52 weeks of treatment. Patients (≥18 years old) were prescribed guselkumab as per routine clinical practice. End points assessed include Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA), target Nail Psoriasis Severity Index (NAPSI), and the Dermatology Life Quality Index (DLQI). Overall, 303 patients were enrolled and treated with guselkumab. Mean disease duration was 21.0 years, and 77.2% and 51.2% of patients had received ≥1 prior conventional systemic or ≥1 prior biologic therapy, respectively. Mean PASI score decreased from 16.4 at baseline to 3.0 by Week (W) 28, and further decreased to 2.4 by W52, while the proportion of patients achieving an absolute PASI score of ≤1 increased from 1.3% at baseline, to 50.8% at W28 and to 58.4% by W52. PASI90 and PASI100 responses also showed marked improvements between W28 and W52, regardless of biologic treatment history. Clearance of psoriatic skin was observed in difficult-to-treat areas, with the percentage of patients achieving a PGA score ≤1 increasing between W28 and W52. Guselkumab improved HRQoL; mean DLQI score decreased from 13.7 at baseline to 2.8 by W28, and further decreased to 2.4 by W52. At W52, 64.6% of patients achieved a DLQI score ≤1. The cumulative probability of drug survival was 92.4% at W52. Guselkumab is efficacious and well tolerated regardless of previous biologic therapies, comorbidities or psoriasis manifestation in difficult-to-treat areas. No new safety signals were observed.
Sections du résumé
BACKGROUND
BACKGROUND
PERSIST was a prospective, non-interventional, long-term, German multicentre study of patients with moderate-to-severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23, in a real-world setting.
OBJECTIVES
OBJECTIVE
Evaluation of the efficacy and safety of guselkumab, and its effect on health-related quality of life (HRQoL), in patients with moderate-to-severe psoriasis who have received 52 weeks of treatment.
METHODS
METHODS
Patients (≥18 years old) were prescribed guselkumab as per routine clinical practice. End points assessed include Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA), target Nail Psoriasis Severity Index (NAPSI), and the Dermatology Life Quality Index (DLQI).
RESULTS
RESULTS
Overall, 303 patients were enrolled and treated with guselkumab. Mean disease duration was 21.0 years, and 77.2% and 51.2% of patients had received ≥1 prior conventional systemic or ≥1 prior biologic therapy, respectively. Mean PASI score decreased from 16.4 at baseline to 3.0 by Week (W) 28, and further decreased to 2.4 by W52, while the proportion of patients achieving an absolute PASI score of ≤1 increased from 1.3% at baseline, to 50.8% at W28 and to 58.4% by W52. PASI90 and PASI100 responses also showed marked improvements between W28 and W52, regardless of biologic treatment history. Clearance of psoriatic skin was observed in difficult-to-treat areas, with the percentage of patients achieving a PGA score ≤1 increasing between W28 and W52. Guselkumab improved HRQoL; mean DLQI score decreased from 13.7 at baseline to 2.8 by W28, and further decreased to 2.4 by W52. At W52, 64.6% of patients achieved a DLQI score ≤1. The cumulative probability of drug survival was 92.4% at W52.
CONCLUSIONS
CONCLUSIONS
Guselkumab is efficacious and well tolerated regardless of previous biologic therapies, comorbidities or psoriasis manifestation in difficult-to-treat areas. No new safety signals were observed.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
guselkumab
089658A12D
Interleukin-23
0
Interleukin-23 Subunit p19
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1568-1577Subventions
Organisme : Janssen-Cilag GmbH (Germany)
Informations de copyright
© 2022 Janssen-Cilag GmbH. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Schafer I, Rustenbach SJ, Radtke M et al. Epidemiology of psoriasis in Germany-analysis of secondary health insurance data. Gesundheitswesen 2011; 73: 308-313.
Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736.
Fortune DG, Richards HL, Griffiths CE et al. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol 2002; 41: 157-174.
Kimball AB, Jacobson C, Weiss S et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392.
Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: implications for management. J Am Acad Dermatol 2017; 76: 393-403.
Seneschal J, Lacour JP, Bewley A et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol 2020; 34: 2566-2573.
Galluzzo M, Tofani L, Lombardo P et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med 2020; 9: 2170.
Augustin M, Eissing L, Langenbruch A et al. The German National Program on psoriasis health care 2005-2015: results and experiences. Arch Dermatol Res 2016; 308: 389-400.
Fehnel S, DeMuro C, McLeod L et al. US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res 2013; 13: 441-446.
Langenbruch A, Radtke MA, Jacobi A et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res 2016; 308: 401-408.
Markham A. Guselkumab: first global approval. Drugs 2017; 77: 1487-1492.
Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405-417.
Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418-431.
Reich K, Griffiths CEM, Gordon KB et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 2020; 82: 936-945.
Reich K, Papp KA, Armstrong AW et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2019; 180: 1039-1049.
Reich K, Armstrong AW, Foley P et al. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study. Am J Clin Dermatol 2020; 21: 881-890.
Reich K, Armstrong AW, Langley RG et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019; 394: 831-839.
Fougerousse AC, Ghislain PD, Reguiai Z et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol 2020; 34: e644-e646.
Malara G, Trifiro C, Bartolotta A et al. Real-world effectiveness and safety of guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci 2021; 25: 406-412.
Maliyar K, O'Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg 2020; 24: 588-595.
Megna M, Fabbrocini G, Cinelli E et al. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat 2020; 33: 1074-1078. https://doi.org/10.1080/09546634.2020.1800577
Rodriguez Fernandez-Freire L, Galan-Gutierrez M, Armario-Hita JC et al. Guselkumab: short-term effectiveness and safety in real clinical practice. Dermatol Ther 2020; 33: e13344.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC et al. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther 2021; 34: e14798.
Snast I, Sherman S, Holzman R et al. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther 2020; 33: e13964.
Gerdes S, Brau B, Hoffmann M et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective. German multicenter PERSIST trial. J Dermatol 2021; 48: 1854-1862. https://doi.org/10.1111/1346-8138.16128
Augustin M, Spehr C, Radtke MA et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges 2014; 12: 48-57.
Iskandar IY, Ashcroft DM, Warren RB et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists biologic interventions register. Br J Dermatol 2015; 173: 510-518.
Armstrong A, Duffin K, Fitzgerald T et al. Impact of guselkumab on quality of life and work productivity outcomes among patients with moderate-to-severe plaque psoriasis in the Corrona Psoriasis Registry. In: 2021 American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX); 23-25 April 2021; poster.
Egeberg A, See K, Garrelts A et al. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol 2020; 20: 3.
da Silva N, Augustin M, Langenbruch A et al. Sex-related impairment and patient needs/benefits in anogenital psoriasis: difficult-to-communicate topics and their impact on patient-centred care. PLoS One 2020; 15: e0235091.
Meeuwis KA, de Hullu JA, van de Nieuwenhof HP et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol 2011; 164: 1247-1255.
Torres T, Puig L, Vender R et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol 2021; 22: 567-579. https://doi.org/10.1007/s40257-021-00598-4
Galluzzo M, D'Adamio S, Campione E et al. A safety evaluation of guselkumab for the treatment of psoriasis. Expert Opin Drug Saf 2018; 17: 741-751.